About this Research Topic
Widespread use of PSA has led to overdiagnosis and ultimately to the overtreatment of low-risk prostate cancer. For bladder cancer and renal cell carcinoma, there are no specific diagnostic, prognostic or predictive biomarkers. Testis cancer is generally silenced at an early stage, leading to the loss of opportunity for early diagnosis and treatment. Non-invasive biomarkers will provide useful tools for personalized medicine. Unfortunately, currently used biomarkers for genitourinary cancers are far from ideal, lacking specificity and sensitivity. Many candidate molecules that act as potential biomarkers for clinical management of patients with prostate, bladder, testis and renal cancers have been proposed. The most encouraging results have been obtained by the combined strategies of: panel of biomarkers and/or clinical variables, which allow to obtain risk indices and therapeutic targets.
The aim is to update the status of the art on non-invasive biomarkers in prostate, kidney, bladder and testicular cancer as well as to present clinical evidence on their use in management of patients from diagnosis to therapy. The articles of the Research Topic will help to highlight recent advances in the field.
The manuscripts should be focused but are not only limited to:
- Diagnostic, prognostic and predictive non invasive biomarkers in urologic cancers
- Animal models and model systems to identify novel biomarkers for urological cancers
- Predictive biomarkers for immunotherapy in urological cancers
- Risk indices for diagnosis and prognosis of urological cancers
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
The aim is to update the status of the art on non-invasive biomarkers in prostate, kidney, bladder and testicular cancer as well as to present clinical evidence on their use in management of patients from diagnosis to therapy. The articles of the Research Topic will help to highlight recent advances in the field.
The manuscripts should be focused but are not only limited to:
- Diagnostic, prognostic and predictive non invasive biomarkers in urologic cancers
- Animal models and model systems to identify novel biomarkers for urological cancers
- Predictive biomarkers for immunotherapy in urological cancers
- Risk indices for diagnosis and prognosis of urological cancers
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: urological cancers, biomarkers, diagnosis, therapeutic targets
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
